^
Association details:
| Biomarker: | FGFR3 G380R |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Excerpt:
Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%....Figure 2b outlines the duration of therapy in individual patients, highlights the most commonly observed FGFR3 alterations, and overall survival.
DOI:
10.1158/2159-8290.CD-18-0229
